A Review of Clinical Studies of
Bropirimine Immunotherapy of
Carcinoma in situ of the Bladder
and Upper Urinary Tract

Sarosdy, Michael F.

doi:10.1159/000474527

Cited by 12 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Loxoribine shows anti-viral and anti-tumor activity in murine animal models since it activates NK cells, B cells and induces various cytokines (Pope et al, 1994;Smee et al, 1990). Bropirimine is an orally active immunomodulator that induces IFN-a and is used for immunotherapy of carcinoma in situ of the bladder and upper urinary tract (Sarosdy, 1997). Overall the synthetic nucleoside analogs are universal compounds for activating TLR7 or TLR8 and may prove useful in the future to modulate immune responses for fighting viral infection or tumors in humans.…”

Section: Tlr7 and Tlr8 Ligandsmentioning

confidence: 99%

Recognition of nucleic acid and nucleic acid analogs by Toll-like receptors 7, 8 and 9

et al. 2008

View full text Add to dashboard Cite

Section: Tlr7 and Tlr8 Ligandsmentioning

confidence: 99%

Recognition of nucleic acid and nucleic acid analogs by Toll-like receptors 7, 8 and 9

et al. 2008

View full text Add to dashboard Cite

“…This compound exhibits anti-tumor and anti-viral activity via activation of NK and B cells to induce multiple cytokines [ 105 , 106 , 107 ]. Bropirimine is an aryl pyrimidinone analogue, an antineoplastic compound that induces IFN-α and is used for treatment of carcinoma [ 108 , 109 ]. The mechanism of action of bropirimine is likely to be direct anti-tumor effect rather than cytokine mediated anti-tumor activity [ 110 ].…”

Section: Nucleic Acid Sensing Tlr Agonists and Their Therapeutic Amentioning

confidence: 99%

Therapeutic Applications of Nucleic Acids and Their Analogues in Toll-like Receptor Signaling

et al. 2012

View full text Add to dashboard Cite

Toll-like receptors (TLRs) belong to a family of innate immune receptors that detect and clear invading microbial pathogens. Specifically intracellular TLRs such as TLR3, TLR7, TLR8 and TLR9 recognize nucleic acids such as double-stranded RNA, single-stranded RNA and CpG DNA respectively derived from microbial components. Upon infection, nucleic acid sensing TLRs signal within endosomal compartment triggering the induction of essential proinflammatory cytokines and type I interferons to initiate innate immune responses thereby leading to a critical role in the development of adaptive immune responses. Thus, stimulation of TLRs by nucleic acids is a promising area of research for the development of novel therapeutic strategies against pathogenic infection, allergies, malignant neoplasms and autoimmunity. This review summarizes the therapeutic applications of nucleic acids or nucleic acid analogues through the modulation of TLR signaling pathways.

show abstract

Blasencarcinome und Carcinome des Übergangsepithels

Köstler¹,

Zielinski²

2001

Urogenitale Carcinome

View full text Add to dashboard Cite

A Review of Clinical Studies of Bropirimine Immunotherapy of Carcinoma in situ of the Bladder and Upper Urinary Tract

Cited by 12 publications

References 18 publications

Recognition of nucleic acid and nucleic acid analogs by Toll-like receptors 7, 8 and 9

Recognition of nucleic acid and nucleic acid analogs by Toll-like receptors 7, 8 and 9

Therapeutic Applications of Nucleic Acids and Their Analogues in Toll-like Receptor Signaling

Blasencarcinome und Carcinome des Übergangsepithels

Contact Info

Product

Resources

About